This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. | Classification codes — C21 (malignant neoplasm of anus and anal canal) |
| B. | Synonyms — anal cancer, anal canal cancer, anal squamous cell carcinoma, anal adenocarcinoma |
| C. | Adult onset — very high (mainly onset in the 50s–70s) |
| 1. | History — the paradigm shift to concurrent chemoradiotherapy with the Nigro protocol (1974); elucidation of the link between HPV and anal cancer |
| 2. | Causes — HPV16/18, HIV infection, anal intercourse, immunosuppression, smoking, multiple sexual partners |
| 3. | Genetics — loss of TP53 and RB1 function due to HPV E6/E7; PIK3CA and KRAS somatic mutations |
| 4. | Epidemiology — less than 1% of all cancers; about 10,000 cases per year in the United States; incidence has risen over the past 20 years |
| 5. | Pathophysiology — sequential progression from HPV → anal intraepithelial neoplasia (AIN) → invasive cancer; mechanism of the E6/E7 oncoproteins |
| 6. | Symptoms — anal bleeding, anal pain, perianal mass, pruritus ani, change in bowel habits |
| 7. | Signs — induration on digital anorectal examination, elevated CEA, inguinal lymphadenopathy |
| 8. | Screening — anal Pap smear for high-risk groups such as HIV-positive individuals and MSM; HPV vaccination (9-valent) |
| 9. | Diagnosis — anoscopic biopsy, CT/MRI staging, PET-CT, AJCC TNM 8th edition, p16 immunohistochemistry |
| 10. | Treatment — mitomycin + 5-FU + radiation (Nigro protocol); salvage abdominoperineal resection; pembrolizumab second-line |
| 11. | Prognosis — 5-year survival rate of 70–90% at early stage; poor prognosis when metastatic; clear differences in prognosis by stage |
| 12. | Prevention — HPV vaccine (Gardasil 9), safe sexual practices, smoking cessation, HIV management and ART |
| 13. | References — 10 items including NCCN anal cancer guidelines, UKCCCR ACT I/II, EXTRA, KEYNOTE-158 |
Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date
| Category | Details |
|---|---|
| ICD-10 code | C21 — Malignant neoplasm of anus and anal canal |
| Subcodes | C21.0 anus, unspecified, C21.1 anal canal, C21.2 cloacogenic zone, C21.8 overlapping lesion of rectum, anus and anal canal |
| Korean Standard Classification of Diseases code | C21 (applied identically under KCD-8) |
| Special Copayment Reduction code | V193 |
| Main histological types | Squamous cell carcinoma (SCC) about 85%, adenocarcinoma about 10%, basaloid carcinoma, melanoma, neuroendocrine tumors, etc. |
Anal cancer, anal canal cancer, anal squamous cell carcinoma, anal adenocarcinoma, malignant tumor of the anal canal, cloacogenic carcinoma, basaloid carcinoma, perianal carcinoma. In English it is written as anal cancer, carcinoma of the anus, or squamous cell carcinoma of the anal canal, and internationally it is common to describe the anal canal and perianal skin regions separately.
Anal cancer is a disease with a very high frequency of adult onset, with a median age at diagnosis of about 60–65 years. However, in HIV-positive patients, men who have sex with men (MSM), and long-term users of immunosuppressants (solid organ transplant recipients), it also occurs at younger ages. It is extremely rare in children and adolescents, and onset before age 40 accounts for 10% or less of all cases. Incidence in women is slightly higher than in men, but since the HIV epidemic, incidence has been rising sharply among MSM.
The most groundbreaking event in the history of anal cancer is the 1974 case report of concurrent chemoradiotherapy (CRT) published by Norman D. Nigro, a surgeon at Wayne State University in the United States. Nigro gave three patients with anal cancer preoperative combined chemoradiotherapy (5-fluorouracil + mitomycin C + radiation 30 Gy) and observed unexpected complete tumor regression. This discovery fundamentally shifted the paradigm of abdominoperineal resection, the standard treatment at the time.
In 1983, Nigro published an expanded case series in the journal Cancer, and over the 1980s–1990s, the UKCCCR ACT I randomized controlled trial in the UK (published 1996) and the EORTC 22861 study (1997) confirmed that CRT is superior to surgery alone. Thereafter, anal cancer treatment shifted firmly from 'surgical removal' to 'organ-preserving concurrent chemoradiotherapy.'
The association between HPV and anal cancer came into focus in the 1980s–1990s alongside the HIV/AIDS epidemic. In 1987, Daling et al. reported markedly elevated HPV antibodies in patients with anal cancer, and molecular biological techniques later demonstrated that HPV16 DNA is detected in about 80–90% of anal cancer tissues. The introduction of Gardasil (quadrivalent HPV vaccine) in 2006 and the approval of Gardasil 9 (9-valent vaccine) in 2014 opened the era of preventing HPV-related anal cancer. In 2012, the ASCRS practice parameters established systematic guidelines for the prevention, diagnosis, and treatment of anal cancer, and a revised edition was published in 2018.
In terms of systemic therapy, the results of the 2021 KEYNOTE-158 basket trial, in which pembrolizumab was effective in advanced MSI-H/TMB-H solid tumors, began to be applied to anal cancer as well, and as of 2025 the NCCN guidelines recommend immune checkpoint inhibitors as second-line treatment for metastatic anal cancer.
Human papillomavirus (HPV) is the most important cause of anal cancer, with HPV DNA detected in about 85–90% of all anal cancers. HPV16 accounts for about 70–75%, and HPV18 for about 10–15%. HPV is transmitted through anal intercourse, mucosal contact, and skin-to-mucosa contact, and with persistent infection it can progress through anal intraepithelial neoplasia (AIN) to invasive cancer.
HIV infection is a strong risk factor for anal cancer. In HIV-positive MSM, the incidence of anal cancer is dozens of times that of the general population, and the risk increases in proportion to the decrease in CD4+ T-cell count. Since the introduction of antiretroviral therapy (ART), HIV-related opportunistic infections have decreased, but the incidence of anal cancer remains markedly higher than in the general population. The risk is also increased in patients taking immunosuppressants after solid organ transplantation and in patients using immunosuppressants for autoimmune diseases.
A history of anal intercourse, multiple sexual partners (5 or more in a lifetime), a history of sexually transmitted infections (STI), and smoking (2–5-fold higher risk in current smokers than in nonsmokers) are known independent risk factors. Chronic anal fistula or scar tissue is also rarely associated with the development of adenocarcinoma.
The molecular genetic features of anal cancer are mostly related to host genomic instability induced by HPV oncoproteins. The HPV E6 oncoprotein degrades TP53 via the ubiquitin-proteasome pathway, blocking p53-mediated cell cycle arrest and apoptosis. The HPV E7 oncoprotein binds the RB1 protein, activating the E2F transcription factor and causing cells to enter the S phase abnormally.
Somatic mutation analysis reports mutations in PIK3CA (about 30%), KRAS (about 10%), FBXW7, and NOTCH1. Tumor mutational burden (TMB) and MSI (microsatellite instability) status are attracting attention as biomarkers predicting response to immuno-oncology therapy, and TMB-H (≥10 mut/Mb) or MSI-H anal cancer falls under the indication for pembrolizumab treatment. Histologically, p16 overexpression is used as a surrogate marker of high-risk HPV infection and has high diagnostic utility. The PD-L1 expression rate in MSS (microsatellite stable) anal cancer overall is reported at about 60–80%, suggesting responsiveness to immunotherapy.
Anal cancer is a rare cancer accounting for less than 1% of all cancer diagnoses. In the United States, about 9,000–10,000 new cases are diagnosed annually, and about 1,800–2,000 people die of it. Incidence has been increasing by about 2–3% per year over the past 20 years, with contributions from the spread of HPV infection, the increasing number of HIV-positive survivors, and enhanced surveillance and diagnosis.
In Korea, anal cancer is classified as a rare cancer, with a few hundred cases per year in national cancer registry statistics. Worldwide, incidence is high in North America, Western Europe, and Oceania and relatively low in Asia. By sex, it is slightly more common in women than in men, but the sex difference is narrowing owing to the surge in incidence among MSM and HIV-positive men. The incidence of anal cancer in HIV-positive MSM is estimated to be 40–100 times that of women in the general population.
The stage distribution at diagnosis is about 50% localized disease (stage I–II), about 30% regionally advanced (stage III), and about 15–20% distant metastasis (stage IV). Metastatic sites are, in order, the liver, lungs, and peritoneum, and inguinal and pelvic lymph node metastases are common.
The pathogenesis of anal cancer is understood as a multistep carcinogenic process from HPV infection to invasive cancer. HPV infection occurs most readily in the squamocolumnar transitional epithelium of the anorectal transition zone (dentate line region, transformation zone). Persistent high-risk HPV infection progresses through anal intraepithelial neoplasia (AIN) I → AIN II → AIN III (high-grade squamous intraepithelial lesion, HSIL) to invasive cancer. This process is similar to the CIN → invasive cancer progression model of cervical cancer.
In terms of molecular mechanisms, HPV E6 forms a complex with E6AP (E6-associated protein), promoting ubiquitination and proteasomal degradation of TP53. As a result, failure of cell cycle arrest upon DNA damage, inhibition of apoptosis, and increased genomic instability occur. HPV E7 binds hyperphosphorylated RB1, releasing E2F and causing overexpression of genes related to cell proliferation (cyclins A, E, etc.). The E5 protein amplifies EGFR signaling. As these molecular changes accumulate, tumor suppressor pathways are completely disabled, and an invasive cancer with the capacity for angiogenesis, local invasion, and distant metastasis forms.
The most common initial symptom of anal cancer is anal bleeding, reported in about 45–50% of all patients. The bleeding is bright red and appears on the stool during defecation or stains the toilet bowl, resembling hemorrhoids, so diagnosis is often delayed. Anal pain or perianal discomfort occurs in about 30%, and severe pain results when the tumor invades the sphincter. Pruritus ani, increased discharge, and perianal masses or ulcers are also common symptoms.
Changes in bowel habits (constipation, tenesmus, narrow stools on defecation) and impaired bowel control (fecal incontinence) may occur, and when the tumor invades the lower rectum, tenesmus becomes severe. In advanced cancer, systemic symptoms such as pelvic pain, an inguinal mass (lymph node metastasis), weight loss, and fatigue are present. When the bladder or vagina is invaded, urinary abnormalities or vaginal discharge may occur.
On physical examination, an indurated mass, ulcer, or irregular mucosal surface in the anus or anal canal is palpated on digital rectal examination (DRE). Inguinal lymphadenopathy suggests metastasis or reactive enlargement, and inguinal lymph node metastasis is found in about 10–20% at diagnosis. Proctoscopy or anoscopy is used to assess the extent of the tumor within the anal canal, its location relative to the dentate line, and sphincter involvement.
On blood tests, CEA (carcinoembryonic antigen) may be elevated, but there is no serum tumor marker specific to anal cancer. Elevated SCC-Ag (squamous cell carcinoma antigen) is observed in some patients. Anemia (chronic bleeding) and liver function abnormalities (with liver metastasis) may accompany it.
There is currently no national standard screening test for anal cancer in the general population. However, screening strategies for high-risk groups are recommended. Anal cytology (anal Pap smear) is performed in HIV-positive men, HIV-positive women, MSM (men who have sex with men), transplant patients taking immunosuppressants, and those with a history of anal intercourse, and abnormal findings are investigated in detail with high-resolution anoscopy (HRA).
HPV vaccination is central to the primary prevention of anal cancer. Gardasil 9 (9-valent HPV vaccine) provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; the US ACIP recommends vaccination for all adolescents and adults aged 26 or younger and considers vaccination at ages 27–45 based on clinical judgment. In Korea, the HPV vaccine for 12-year-old girls is included in the National Immunization Program (NIP). For HIV-positive patients, maintaining immune function with ART is important for reducing the risk of anal cancer.
A histological diagnosis is established by anoscopic or endoscopic biopsy of suspicious lesions. p16 immunohistochemical staining is performed to determine HPV infection, and strong p16 positivity suggests high-risk HPV infection. Squamous cell carcinoma accounts for about 85%, and adenocarcinoma (10%) requires differentiation from rectal cancer.
Pelvic MRI is the most useful test for evaluating tumor size, the extent of sphincter involvement, and pelvic lymph node metastasis. Abdominopelvic CT is used to evaluate distant metastasis (liver, lung, peritoneum). PET-CT is excellent for functional evaluation of lymph node metastasis and detection of distant metastasis and is also used for radiation therapy planning. Endorectal ultrasound (ERUS) is used as an adjunct for evaluating sphincter involvement.
The AJCC TNM classification (8th edition) is used. The T stage is based on tumor size (T1: ≤2 cm; T2: 2–5 cm; T3: >5 cm; T4: invasion of adjacent organs), and the N stage is divided by involvement of perirectal, inguinal, and internal iliac lymph nodes. M1 indicates distant metastasis. Perianal cancer (classified as C44) is classified separately as skin cancer.
The standard treatment for all localized anal cancers except T1N0 is combined mitomycin C + 5-fluorouracil (5-FU) + radiation (an evolved form of the Nigro protocol). The total radiation dose is 54–59.4 Gy (fractionated), and intensity-modulated radiation therapy (IMRT) is used to minimize normal tissue toxicity. In the large randomized trials RTOG 9811 and UKCCCR ACT II, mitomycin + 5-FU + radiation was established as standard. Cisplatin-based protocols are inferior to mitomycin-based ones and are not currently recommended.
Early T1N0 anal margin cancer can be treated with wide local excision. Salvage abdominoperineal resection (salvage APR) is performed for residual or recurrent tumors after CRT. The 5-year survival rate after APR is about 30–60%.
Carboplatin + paclitaxel is mainly used as first-line treatment for metastatic anal cancer, and cisplatin + 5-FU is also an option. As second-line treatment, pembrolizumab (a PD-1 inhibitor) is effective in MSI-H/TMB-H tumors or PD-L1-positive tumors and is included in the NCCN guidelines. A recent clinical trial of atezolizumab + bevacizumab combination therapy (published 2025) reported a partial response rate of about 17% and a disease control rate of about 60% in HPV-positive metastatic anal cancer.
Anal cancer has a relatively favorable prognosis compared with other gastrointestinal malignancies. The 5-year overall survival rate for early-stage disease (stage I–II) reaches 70–90%, and more than 90% is reported especially for T1N0 lesions. The 5-year survival rate for locally advanced disease (stage III) is about 50–60%, and for distant metastasis (stage IV) it is poor at less than 10–20%.
Important prognostic factors include stage (the most important), tumor size (>5 cm unfavorable), inguinal lymph node metastasis, immunosuppressed status (HIV positivity unfavorable), and treatment response (whether complete remission is achieved). Patients who achieve a complete clinical response (cCR) after CRT have excellent long-term survival. MSI-H/TMB-H tumors show higher response rates to immuno-oncology therapy and may therefore be prognostically favorable.
Primary prevention: HPV vaccination is the most effective means of primary prevention. Gardasil 9 (9-valent HPV vaccine) is more than 95% effective in preventing high-risk HPV infection when given before sexual debut. In Korea, national immunization of 12-year-old girls is in place, and expanded use for boys and girls aged 12–17 and women aged 18–26 is recommended. Safe sexual practices (condom use) reduce the risk of HPV transmission but do not block it completely.
Secondary prevention: In high-risk groups such as HIV-positive individuals and MSM, early detection and treatment of AIN (anal intraepithelial neoplasia) through anal cytology and high-resolution anoscopy inhibit progression to invasive cancer. In people with HIV, maintaining immune function with ART contributes to reducing the risk of anal cancer. Smoking cessation and limiting the number of sexual partners are also recommended.